Loïc Vincent, PhD, serves as Chief Scientific Officer at Korro Bio Inc., a clinical-stage biotechnology company pioneering RNA editing therapies for genetic diseases. With over 25 years of experience in drug discovery and development, particularly in oncology and RNA therapeutics, Dr. Vincent brings a wealth of expertise to his role. He earned his PhD in vascular biology from the University of Paris and conducted postdoctoral research at Memorial Sloan Kettering Cancer Center, where he pioneered studies on angiogenesis and the tumor microenvironment. His career progressed through leadership positions at Inserm, where he advanced preclinical models for anti-angiogenic therapies, and later at Takeda Pharmaceutical, rising to Vice President of Research in Oncology, overseeing global R&D pipelines. Dr. Vincent's achievements include leading the discovery of novel therapeutic targets in solid tumors, contributing to multiple IND filings, and publishing over 50 peer-reviewed papers in high-impact journals such as Nature Medicine and Cancer Cell. At Takeda, he spearheaded programs that advanced several candidates into clinical trials, demonstrating his prowess in translating basic science into viable therapeutics. His work has been recognized with awards from the French National League Against Cancer and the American Association for Cancer Research. At Korro Bio, Dr. Vincent directs the scientific strategy, overseeing the development of the company's proprietary RNA editing platform, including lead programs like KRRO-110 for alpha-1 antitrypsin deficiency. His vision integrates cutting-edge editing technologies with rigorous preclinical validation to accelerate transformative treatments, positioning Korro at the forefront of genetic medicine innovation.